Celcuity Inc.
CELC
Positions held
Your positionsCELC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Celcuity Inc. is positioned in the biotechnology sector, focusing on innovative cancer therapies, which could benefit from increasing demand in personalized medicine.
- The company's market cap stands at approximately $3.49 billion, indicating significant investor interest.
- Despite current challenges, analysts have a strong buy recommendation with a target mean price of $156.91.
- Celcuity has reported zero revenue for multiple quarters, raising concerns about its operational viability.
- The company has consistently posted negative net income, with a loss of $78.86 million in Q2 2026.
- Current financial indicators show a strong sell signal with a score of -24.00, reflecting negative trends and bearish market conditions.
Fundamentals
| Market cap | $3.32B | Enterprise value | $3.32B | Trailing P/E | — | Forward P/E | -848.38 |
| PEG | — | Price / book | -260.04 | Beta | 0.11 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -14.3% | ROA | -25.8% | Debt / equity | — |
| Current ratio | 8.93 | Free cash flow | -$72.00M | Analyst recommendation | strong_buy | Mean target | $156.91 |
| 52w high | $151.02 | 52w low | $45.03 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$78.9M | -$52.8M | -$51.0M | -$43.8M | -$45.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$66.1M | -$50.5M | -$49.2M | -$42.8M | -$44.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$177M | -$112M | -$63.8M | -$40.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$172M | -$113M | -$66.2M | -$39.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event
2026-10-05 · Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
2026-10-03 · Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?
2026-10-02 · Celcuity Appoints David Gryska To Its Board Of Directors
2026-09-30 · Why Celcuity Stock Was a Winner on Wednesday
2026-09-30 · Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
2026-09-28 · Is Celcuity (CELC) Stock a Buy?
2026-09-17 · JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target
2026-09-01 · Celcuity To Participate in Upcoming Investor Conferences
2026-08-27 · Celcuity (CELC): Landmark Approval Collides With A Costly Launch
2026-08-26 · Celcuity Submits Supplemental NDA for REVTORPYK in PIK3CA-Mutant Breast Cancer
Price (daily)
Full chart · RSI · MACD · patterns